Abstract
An increasing percentage of patients with new-onset seizures are HIV positive. The evaluation and management is distinctly different from managing the non-HIV-infected patient. Clinicians must be familiar with comorbid infectious etiologies and the relative value of electroencephalogram, imaging, and serum and cerebrospinal fluid laboratory tests. Traditional antiepileptic drug (AED) therapies are contraindicated and may lead to increased HIV viral replication through either directed cellular mechanisms or interference with antiretroviral therapies. Newer AEDs have pharmacokinetic properties that make them reasonable choices, although none have been specifically studied for efficacy or safety in HIV. Lastly, optimal choice of an AED should reflect commonly encountered neurologic and psychiatric comorbidities.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Sempre AP, Villaverde FJ, Martinez-Menendez B, et al.: First seizure in adults: a prospective study from the emergency department. Acta Neurol Scand 1992, 86:134–138.
Bartolomei F, Pellegrino P, Dhiver C, et al.: Epilpetic Seizures in HIV infection. 52 cases. Presse Med 1991, 20:2135–2138.
Chada DS, Handa A, Sharma SK, et al.: Seizures in patients with human immunodeficiency virus infection. J Assoc Phys India 2000, 48:573–576.
Primavera A, Solaro C, Cocito L: De novo status epilepticus as the presenting sign of neurosyphllis. Epilesia 1998, 39:1367–1369.
Lechner C, Auer D, Kumfel T, et al.: Prolonged non-convulsive status epilepticus as an early clinical manifestation of epilepsy in connection with HIV infection—case report with EEG and MRI follow up. Fortschritte Der Neurologie-Psychiatrie 1998, 66:326–330.
Bartolomei F, Gavaret M, Dhiver C, et al.: Isolated, chronic, epilepsia partialis coontinua in an HIV-infected patient. Arch Neurol 1999, 56:111–114.
Moulignier A, Mikol J, Pialoux G, et al.: AIDS-associated progressive multifocal leukoencephalopathy revealed by newonset seizures. Am J Med 1995, 99:64–68.
Marsan A, Zivin LS: Factors related to the occurrence of typical paroxysmal abnormalities in the EEG records of epileptic patients. Epilepsia 1970, 11:361–381.
Bakshi R: Neuroimaging of HIV and Aids related illnesses: a review. Frontiers Biosci 2004, 9:632–646. Important study.
Thurner M, Thurner S, Fleischmann D, et al.: Comparison of T2-weighted and fluid-attenuated inversion-recovery fast spin-echo MR sequences in intracerebral AIDs-associated disease. Am J Neuroradiol 1997, 18:1601–1609.
Chinn R, Wilkinson I, Hall-Craggs M, et al.: Toxoplasmosis and primary central central nervous system lymphoma in HIV infection: diagnosis with MR spectroscopy. Radiology 1995, 197:649–654.
Villringer K, Jager H, Dichgans M, et al.: Differential diagnosis of CNS lesions in AIDS by FDG-PET. J Comput Assist Tomogr 1995, 19:532–536.
Update: serologic testing for HIV-1 antibody—United States, 1988 and 1989. Morb Mortal Wekly Rep 1990, 39:380-383.
Sloand EM, Pitt E, Chiarello RJ, Nemo GJ: HIV testing. State of the art. JAMA 1991, 266:2861.
Chraetien F, Baelec L, Hilton DA, et al.: Herpes simplex virus type 1 encephalitis in acquired immunodeficiency syndrome. Neuropathol Appl Neurobiol 1996, 22:394.
Hamilton RL, Achim C, Grafe MR, et al.: Herpes simplex virus brainstem encephalitits in an AIDS patient. Clin Neuropathol 1995, 14:45.
Modi G, Martinus I, Vangu M: New onset seizures in HIVinfected patients without intracranial mass lesions or meningitis —a clinical, radiological and SPECT scan study. J Neurol Sci 2002, 202:29–34.
Pesola GR, Westfal RE: New-onset seizures in patients with AIDS presenting to an emergency department. J Neurol Sci 1998, 161:180–184.
Morgello S, Black G, Price R, et al.: Varicella-zoster virus leukoencephalitis and cerebral vasculopathy. Arch Pathol Lab Med 1998, 112:173.
Pierson T, McArthur J, Silicano RF: Reservoirs of HIV-1 infection: mechanism for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000, 18:665–708.
Stingele K, Haas J, Zimmermann T, et al.: Independent HIV replication in paired CSF and blood viral isolate during antiretroviral therapy. Neurology 2001, 5655–5361.
Hugen PW, Burger DM, Brinkman K, et al.: Carbamazepine-indinivar interaction causes antiretroviral therapy failure. Ann Pharmacother 2000, 34:465–470.
Kato Y, Fuji T, Mizoguchi N, et al.: Potential interaction between ritonavir and carbamezipine. Pharmacotherapy 2000, 20:851–854.
Leppik IE, Gapany S, Walczak T: An HIV positive patient with epilepsy. Epilepsy Behav 2003, 4:S17-S19.
Witvrouw M, Schnidt JC, Van Remoortel B: Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retroviruses 1997, 13:187–192.
Simon G, Moor C, Obert G: Valproic acid reduces the intracellular level of glutathione and stimulates human immunodeficiency virus. Chem Biol Interact 1994, 91:111–121.
Cozza KL, Swanton EJ, Humphreys CW: Hepatotoxicity with a combination of valproic acid, ritonavir, and nevirapine: a case report. Psychomatics 2000, 41:452–453.
Pardo CA, McArthur JC, Griffin JW: HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Periph Nerv Syst 2001, 6:21–31.
Vitiello B, Burnam MA, Bing E, et al.: Use of psychotropic mediations among HIV-infected patient in the United States. Am J Psychiatry 2003, 160:547–554.
La Spina I, Porazzi D, Maggiolo F, et al.: Gabapentin in painful HIV-related neuropathy: a report of 19 patients preliminary observations. Eur J Neurol 2001, 8:71–75.
Brodie MJ, Chadwick DW, Anhut H, et al.: Gabapentin versus lamotrigine monotherapy: a double-blinded comparison in newly diagnosed epilepsy. Epilepsia 43:993–1000.
Shank RP, Gardocki JF, Streeter AJ, et al.: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetecs, and mechanism of action. Epilepsia 2000, 41(suppl 1):S3-S9.
Garnet WR: Clinical pharmacology of topiramate: a review. Epilepsia 2000, 41(suppl 1):S61-S65.
Doose RD, Jacobs D, Squires L, et al.: Oral contraceptive-AED interactions: no effect of topiramate as monotherapy at clinically effective dosages of 200 mg or less. Paper presented at the American Epilepsy Society. Seattle, WA, December, 2002.
Janowsky DS: New treatments of bipolar disorder. Curr Psychiatry Rep 1999, 1:111–113.
Kline KM, Carroll DG, Malnar KF: Painful diabetic peripheral neuropathy relieved with the use of oral topiramate. South Med J 2003, 96:602–605.
Simpson D, Olney R, Mcarthur J, et al.: A placebo-controlled trial of lamotrigine for painful HIV associated neuropathy. Neurology 2000, 54:2115–2119.
Fiorenzo A, Roberto R, Agostino B: Oxcarbazapine interactions with other drugs. In Antiepileptic Drugs, edn 5. Edited by Levy RH, Mattson RH, Meldrum BS, Bashir KH. Philadelphia: Lippincott Williams & Wilkins; 2002:464–475.
Kramer G: Oxcarbazepine adverse effects. In Antiepileptic Drugs, edn 5. Edited by Levy RH, Mattson RH, Meldrum BS, Bashir KH. Philadelphia: Lippincott Williams & Wilkins; 2002:482–483.
Biton V: Levetiracetam adverse experiences. In Antiepileptic Drugs, edn 5. Edited by Levy RH, Mattson RH, Meldrum BS, Bashir KH. Philadelphia: Lippincott Williams & Wilkins; 2002:441–447.
Drug information Handbook 2002–2003, edn 10. Hudson, OH: Lexicomp; 2002:747–749.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mullin, P., Green, G. & Bakshi, R. Special populations: The management of seizures in HIV-positive patients. Curr Neurol Neurosci Rep 4, 308–314 (2004). https://doi.org/10.1007/s11910-004-0057-x
Issue Date:
DOI: https://doi.org/10.1007/s11910-004-0057-x